Director Jeffrey M. Rowe filed a Form 4 with the SEC on November 17, 2026, disclosing the acquisition of Stock Appreciation Rights in Zomedica Corp. (ZOMDF) on November 16, 2026.

Key Highlights

  • Reporting person: Jeffrey M. Rowe, identified in the filing as a Director of Zomedica Corp.
  • Security acquired: 2,126,959 Stock Appreciation Rights (SARs) with a conversion/exercise price of $0.10, acquired on November 16, 2026.
  • Expiration date: The SARs expire on November 15, 2036, and become exercisable beginning November 15, 2027, according to the filing.
  • Price of derivative security: The filing records the price of the derivative security as $0.
  • Resulting holdings: Following the transaction, Rowe beneficially owns 2,126,959 SARs directly, as reported in the filing.
  • Underlying security: The SARs are linked to 2,126,959 shares of Zomedica common stock, per the filing.

Zomedica Director Rowe Acquires Stock Appreciation Rights on November 16, 2026

According to the Form 4 filed on November 17, 2026, Jeffrey M. Rowe, a Director of Zomedica Corp. (ZOMDF), acquired 2,126,959 Stock Appreciation Rights on November 16, 2026. The transaction is recorded under Table II (Derivative Securities) with transaction code "A," indicating an acquisition. The exercise price of the SARs is listed as $0.10, and the price of the derivative security at the time of the transaction is recorded as $0.

The filing states that the SARs have a date exercisable of November 15, 2027, and an expiration date of November 15, 2036. The underlying security tied to these SARs is Zomedica common stock, with the number of underlying shares equal to 2,126,959. Following this transaction, the filing reports that Rowe directly holds 2,126,959 derivative securities beneficially owned.

No transactions were reported in Table I (Non-Derivative Securities) in connection with this filing. The form was signed by Jeffrey Rowe and dated November 17, 2026. No amendment date is indicated, suggesting this is an original filing. The filing identifies Rowe's address as 1101 Technology Drive, Suite 100, Ann Arbor, Michigan 48108.

What Was Disclosed

Zomedica Corp. Director Jeffrey M. Rowe disclosed the acquisition of 2,126,959 Stock Appreciation Rights on November 16, 2026, exercisable beginning November 15, 2027, expiring November 15, 2036, with an exercise price of $0.10 per the Form 4 filing.